Associates
Bruce Wieland
Dr. Wieland is in the thirty-fourth year of his engineering research career in the field of accelerator target systems for the production of radionuclides used for PET and therapy applications in nuclear medicine. He is a Certified Professional Engineer and holds a BS in Mechanical Engineering and PhD in Nuclear Engineering. His numerous targetry innovations and inventions include the installation of novel stable enriched isotope targets for the production of the positron-emitting radionuclides C-11, N-13, O-15, and F-18. In addition to cyclotron and PET targetry improvements, he developed a target for the production of O-15 ozone used for lung penetration studies in animals, and an internal target for the alpha production of At-211 used to label monoclonal antibodies for brain tumor therapy. Dr. Wieland is currently the president of Bruce Technologies, Inc., and the principal investigator on two NIH research grants awarded to his company for the development of recently patented inventions. The goal of these inventions is to significantly increase the level of F-18 that can be produced by available beam currents, through retrofitting existing accelerators and utilization on future cyclotrons.